Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients DOI Creative Commons
Susana Patricia Amaya Hernandez, Ditte Stampe Hersby, Kamilla Kjærgaard Munk

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 13

Published: Jan. 10, 2023

Patients with hematological malignancies are prioritized for COVID-19 vaccine due to their high risk severe SARS-CoV-2 infection-related disease and mortality. To understand T cell immunity, its long-term persistence, correlation antibody response, we evaluated the BNT162b2 mRNA vaccine-specific immune response in chronic lymphocytic leukemia (CLL) myeloid dysplastic syndrome (MDS) patients. Longitudinal analysis of CD8 + cells using DNA-barcoded peptide-MHC multimers covering full Spike-protein (415 peptides) showed activation persistence memory up six months post-vaccination. Surprisingly, a higher frequency vaccine-induced antigen-specific was observed patient group compared healthy donor group. Furthermore, importantly, immunization second booster dose significantly increased as well total number specificities. Altogether 59 vaccine-derived immunogenic responses were identified, which 23 established strong immunodominance NYNYLYRLF (HLA-A24:02) YLQPRTFLL (HLA-A02:01) epitopes. In summary, mapped booster-specific enrichment that could be important protection this

Language: Английский

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety DOI Open Access
Annika Fendler, Elisabeth G.E. de Vries, Corine H. GeurtsvanKessel

et al.

Nature Reviews Clinical Oncology, Journal Year: 2022, Volume and Issue: 19(6), P. 385 - 401

Published: March 11, 2022

Language: Английский

Citations

179
COVID-19 in patients with hematologic malignancy DOI Open Access
Petra Langerbeins, Michael Hallek

Blood, Journal Year: 2022, Volume and Issue: 140(3), P. 236 - 252

Published: May 11, 2022

Language: Английский

Citations

110
Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis DOI Open Access
Andrea Becerril‐Gaitan, Bryan F. Vaca‐Cartagena, Ana S. Ferrigno

et al.

European Journal of Cancer, Journal Year: 2021, Volume and Issue: 160, P. 243 - 260

Published: Oct. 27, 2021

Language: Английский

Citations

109
SARS-CoV-2 in immunocompromised individuals DOI Creative Commons
Susan DeWolf, Justin Laracy, Miguel‐Angel Perales

et al.

Immunity, Journal Year: 2022, Volume and Issue: 55(10), P. 1779 - 1798

Published: Sept. 13, 2022

Language: Английский

Citations

92
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer DOI Open Access
Annika Fendler, Scott T.C. Shepherd, Lewis Au

et al.

The Lancet, Journal Year: 2022, Volume and Issue: 399(10328), P. 905 - 907

Published: Jan. 25, 2022

Language: Английский

Citations

82
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review DOI Creative Commons

Nick Pooley,

Salim S. Abdool Karim, Béhazine Combadière

et al.

Infectious Diseases and Therapy, Journal Year: 2023, Volume and Issue: 12(2), P. 367 - 387

Published: Jan. 9, 2023

Vaccines developed against SARS-CoV-2 have proven to be highly effective in preventing symptomatic infection. Similarly, prior infection with has been shown provide substantial protection reinfection. However, it become apparent that the provided an individual after either vaccination or wanes over time. Waning is driven by both waning immunity time since initial infection, and evolution of new variants SARS-CoV-2. Both antibody T/B-cells levels investigated as potential correlates post-vaccination post-infection. The activity antibodies some insight into underlying causes protection. This review seeks summarise what currently known about and/or well current information on respective T/B-cell responses.

Language: Английский

Citations

68
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study DOI Creative Commons
Annika Fendler, Lewis Au, Scott T.C. Shepherd

et al.

Nature Cancer, Journal Year: 2021, Volume and Issue: 2(12), P. 1321 - 1337

Published: Oct. 27, 2021

Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling clinical annotation. Of 357 patients cancer, 118 were SARS-CoV-2 positive, 94 symptomatic 2 died of COVID-19. In this cohort, 83% had S1-reactive antibodies 82% neutralizing against wild type SARS-CoV-2, whereas antibody titers Alpha, Beta Delta variants substantially reduced. levels decreased in 13% patients, remained stable for up to 329 days. also detectable SARS-CoV-2-specific T cells CD4

Language: Английский

Citations

85
Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review DOI Creative Commons
Amir Bahador Boroumand, Mahtab Forouhi, Farzaneh Karimi

et al.

Frontiers in Immunology, Journal Year: 2022, Volume and Issue: 13

Published: Aug. 29, 2022

To evaluate the immunogenicity of COVID-19 vaccines in patients with diabetes mellitus (DM) through a systematic approach.A comprehensive search was conducted PubMed, Scopus, and Web Science no time restrictions. The based on three main concepts: Covid-19, Vaccine Diabetes Mellitus.After excluding irrelevant studies, 16 studies remained for quantitative assay. Among sixteen eleven had controls. Type specifically mentioned six (T2DM; n=4, T1DM T2DM; n=2). Twelve included were that mRNA (i.e. BNT162b2 mRNA-1273) DM, five vector-based Ad5-nCoV ChAdOx1-S), assessed including inactivated BBV-152, CoronaVac, Sinopharm or SinoVac). Most current indicate lower antibody response DM compared to individuals without after second dose vaccine irrespective type. Several have shown higher age BMI are associated response, while optimum glycemic control GFR among DM.Immunogenicity has mostly been reported be healthy There also few assessing variables significantly affect this association, age, type diabetes, BMI, eGFR. Investigating these associations could help us provide most advantageous condition before, during vaccination response. Many unresolved issues concerning potential factors affecting immunogenicity, vaccine, numbers administered doses, re-vaccination intervals hyperglycemia need addressed future research.

Language: Английский

Citations

58
The prevalence of adaptive immunity to COVID-19 and reinfection after recovery – a comprehensive systematic review and meta-analysis DOI Creative Commons
Tawanda Chivese, Joshua T. Matizanadzo, Omran A. H. Musa

et al.

Pathogens and Global Health, Journal Year: 2022, Volume and Issue: 116(5), P. 269 - 281

Published: Jan. 31, 2022

This study aims to estimate the prevalence and longevity of detectable SARS-CoV-2 antibodies T B memory cells after recovery. In addition, COVID-19 reinfection preventive efficacy previous infection with were investigated. A synthesis existing research was conducted. The Cochrane Library, China Academic Journals Full Text Database, PubMed, Scopus, preprint servers searched for studies conducted between 1 January 2020 April 2021. Included assessed methodological quality pooled estimates relevant outcomes obtained in a meta-analysis using bias adjusted method. Proportions synthesized Freeman-Tukey double arcsine transformation binary odds ratio (OR). Heterogeneity I2 Cochran's Q statistics publication Doi plots. Fifty-four from 18 countries, around 12,000,000 individuals, followed up 8 months recovery, included. At 6–8 specific immunological remained high; IgG – 90.4% (95%CI 72.2–99.9, = 89.0%), CD4+ 91.7% 78.2–97.1y), 80.6% 65.0–90.2) 0.2% 0.0–0.7, 98.8). Individuals previously infected had an 81% reduction (OR 0.19, 95% CI 0.1–0.3, 90.5%). Around 90% recovered individuals evidence SARS-CoV-2, at recovery low risk reinfection.RegistrationPROSPERO: CRD42020201234

Language: Английский

Citations

46
Understanding Immune Responses to Viruses—Do Underlying Th1/Th2 Cell Biases Predict Outcome? DOI Creative Commons
Faith Howard, Amy Kwan,

Natalie Winder

et al.

Viruses, Journal Year: 2022, Volume and Issue: 14(7), P. 1493 - 1493

Published: July 8, 2022

Emerging and re-emerging viral diseases have increased in number geographical extent during the last decades. Examples include current COVID-19 pandemic recent epidemics of Chikungunya, Ebola, Zika viruses. Immune responses to viruses been well-characterised within innate adaptive immunity pathways with outcome following infection predominantly attributed properties virus circumstances infection. Perhaps belief that immune system is often considered as a reactive component host defence, springing into action when threat detected, has contributed poorer understanding inherent differences an individual’s absence any pathology. In this review, we focus on how these factors (age, ethnicity, underlying pathologies) may skew T helper cell response, thereby influencing but also whether can use biases predict patients at risk deviant response apply strategies avoid or overcome them.

Language: Английский

Citations

39